Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. - Wikidata - wikimedia - TriplyDB

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

http://www.wikidata.org/entity/Q33584851

about

Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment Therapeutic cancer vaccines: past, present, and future Reciprocal relationship between myeloid-derived suppressor cells and T cells Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues Regulation of tumor metastasis by myeloid-derived suppressor cells The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Phenotype, development, and biological function of myeloid-derived suppressor cells Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Orchestration of angiogenesis by immune cells Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Coordinated regulation of myeloid cells by tumours The functions and clinical applications of tumor-derived exosomes Reciprocal relationship of T regulatory cells and monocytic myeloid-derived suppressor cells in LP-BM5 murine retrovirus-induced immunodeficiency The use of immunotherapy in the treatment of melanoma Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells CD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseases Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection.Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.New roads open up for implementing immunotherapy in mesothelioma.The pre-metastatic niche: finding common ground.Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells.Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice.Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.Anti-HMGB1 monoclonal antibody ameliorates immunosuppression after peripheral tissue trauma: attenuated T-lymphocyte response and increased splenic CD11b (+) Gr-1 (+) myeloid-derived suppressor cells require HMGB1.Myeloid-derived suppressor cells: paradoxical roles in infection and immunity.Δ9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8 Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity.A novel subset of B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC.

P2860

Q26741252-1F73EB79-AA41-4C41-9DDB-ABAEE820CECC Q26746986-1C97573B-3A59-4F4D-823B-4C615295F3BE Q26799126-88D614F2-D04C-4DF4-8576-542F06989BC4 Q26863283-41127415-2B03-40A5-83FE-C9E599BC040C Q27000664-82F73DDF-F460-46D1-A944-F0D309CE1431 Q27001081-67AA9545-61FC-4029-826D-A783A7EABAFA Q27003907-F8B2DA0A-319C-4776-8926-AFDB2ED6F5C2 Q27022125-DE51E3FC-9769-4BB5-8E1C-EA0834EDCF76 Q28076760-7304B1AD-0EBB-47F2-940E-A63B57D90A01 Q28079046-22B39BB0-A5FD-4B94-9A28-AD9AAB36A65B Q28080262-A1F24444-7D94-4F3C-8B7B-288058527FFD Q28082461-13F86D0B-7491-487D-A540-A0B0ADBCE491 Q28388630-A02B068C-5781-4734-8187-9A34D305A5FD Q28389236-8F617A4A-5E40-4DCE-A6B8-D9CD8F2E14DF Q28393614-642FD0EC-2751-41ED-8EAE-FA7FD2A818F3 Q28395157-A2E7D277-3DEE-460C-AD68-41839CC6E620 Q30361738-DDEB284F-107C-418C-8BA0-138CC12CA8E9 Q33573202-8539E140-AF8E-40E5-B8E6-8F4CA3FD7D4B Q33593858-B38D7A76-691D-4C61-8104-6C6CAD5AC671 Q33606156-81A83ECA-A55D-4EF0-BCB1-66CD9EF1593D Q33732210-479F8CA4-E7E1-48DF-BD93-66ECAB7D2438 Q33754157-44C9FF21-ADB9-43AF-8EC4-A66BA26E64F4 Q33844271-60A6C8F6-96B1-4FDA-A91D-ADDBCF043DED Q33889439-D1AAEB36-0585-4BFB-883B-FE4559F072E9 Q34243443-6D6DB016-B101-4C08-89A4-149E362227C5 Q34315871-E52B73C9-6466-4489-A31C-FED6834C4537 Q34331993-7046E3C6-2641-4588-AC73-AAC3A27DA4C2 Q34342357-5BB088D0-D2A1-46B1-ABBF-09AFB5075AE9 Q34461732-F630FD09-2E44-4392-8BDB-214B06922606 Q34502899-2C29EEE1-BC12-4216-8F54-91B6317AAA17 Q34550822-0583F3C7-B203-4AA5-A7F4-EDC0CA4F2FE8 Q34699543-64B32D08-1958-4042-B7EB-FF7CB096C943 Q34723007-2C11A23F-5399-4BD9-8DA3-0CBC9C06B294 Q34903354-7021287F-133E-415A-ADD9-7A89C25EDB4C Q35044328-1D5022A5-7C47-4EA1-B38D-8D42DA110EA1 Q35076030-78D4DB67-2578-4DFB-8F05-7841C55F9AD4 Q35143001-66DD0B28-3F6C-4666-992E-172BE6F9828A Q35207111-78E2457C-292E-41B5-8392-8D3CBD89A224 Q35227738-F1D532F1-B364-4698-8B2D-B862DF21DB15 Q35506243-74612E74-496B-4FF7-8E26-004E08ECF93A

P2860

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

http://www.wikidata.org/entity/Q33584851

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@ast

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@en

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@nl

type

label

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@ast

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@en

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@nl

prefLabel

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@ast

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@en

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@nl

P1433

Q33584851-89DB14B2-AB9F-44F8-BF1B-C9136BF80BEB

P1476

Q33584851-E848E11C-BFFB-4E39-8F20-6BA66B05EB12

P2093

Q33584851-1DB8511C-072C-49BE-917E-2824326B030D

Q33584851-5CFFF80D-039A-4DED-859F-34AE4E4F35DD

Q33584851-7B358686-3B98-48BE-ADE5-410FAC3103FD

Q33584851-A4A0416E-4318-4004-8775-BBA1616AF353

Q33584851-B2701FA8-CF74-4A77-9798-2B3DB167F1FA

Q33584851-B46835F8-C667-4394-AE74-9ADF00B08520

Q33584851-BE53CA0F-A18F-470B-B8F0-C232986EDAB9

Q33584851-F0741BAD-4EEB-4A34-97C0-5C9B27FF2028

P2860

Q33584851-148703E2-21FC-4F35-BFC8-B6316440DF3D

Q33584851-14F4AF3B-28DA-46F9-9FDA-101A6DF9FC67

Q33584851-1E73489F-54D4-4E6C-B7A4-0DB267D42227

Q33584851-206A1BE4-58AE-45F7-99BE-C4E2D0E5AA59

Q33584851-2241643F-4F53-40DE-AF38-C98EC2FA9BEB

Q33584851-27107455-A19E-4C3A-A2A9-58ECAE6382E1

Q33584851-2725FA1B-B92A-4D83-8BDA-B6ED1CF1F029

Q33584851-2DDCD6F4-D83D-4428-B28E-F5A6BA2EFE05

Q33584851-41E58588-9C38-4C8B-B14A-757EADC608E8

Q33584851-45BA3806-51F1-49AF-BC21-2EB8A8CB73F3

P304

Q33584851-E1603305-F5F9-48B0-9F60-DAC098956AD4

P31

Q33584851-EB5ACDDD-88A4-4450-A481-6C1079C40E95

P356

Q33584851-7D30602D-4580-442F-9B24-EB5555BAD655

P407

Q33584851-1A834BCB-4EEF-4716-A657-367BAF16CE55

P433

Q33584851-C323156F-8C77-4B26-ACE2-3C9D89789E10

P478

Q33584851-7A839133-4BA2-4373-BEC9-4DC3816A7720

P577

Q33584851-B0C142B5-32C2-41E4-AAFD-7FDFE5CB20A3

P5875

Q33584851-6779617B-11D3-4B3B-9811-39E55B7FEB45

P698

Q33584851-7402C683-31D7-4FCD-98EC-51B3E1DD8CDD

P932

Q33584851-C6EED8B2-53C0-4B4C-BAF0-2F1C4A43D270

P356

0008-5472.CAN-09-1882

P1433

Cancer Research

P1476

Immune stimulatory receptor CD ...... ed suppressor cells in cancer.

@en

P2093

Bingjiao Yin

http://www.w3.org/2001/XMLSchema#string

Celia M Divino

http://www.w3.org/2001/XMLSchema#string

Ge Ma

http://www.w3.org/2001/XMLSchema#string

George Wang

http://www.w3.org/2001/XMLSchema#string

Junko Ozao-Choy

http://www.w3.org/2001/XMLSchema#string

Kaare J Weber

http://www.w3.org/2001/XMLSchema#string

Ping-Ying Pan

http://www.w3.org/2001/XMLSchema#string

Shu-Hsia Chen

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

Adoptive immunotherapy for cancer: building on success

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.

Tregs and rethinking cancer immunotherapy.

CD40/CD154 interactions at the interface of tolerance and immunity.

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.

Emerging possibilities in the development and function of regulatory T cells.

P304

99-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-1882

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40483118

http://www.w3.org/2001/XMLSchema#string

P698

19996287

http://www.w3.org/2001/XMLSchema#string

P932

2805053

http://www.w3.org/2001/XMLSchema#string